20cm速递|关注创业板医药ETF国泰（159377）投资机会，行业长期投资机会来自创新、出海和并购整合

Group 1 - The core investment opportunities in the medical device industry stem from innovation, international expansion, and mergers and acquisitions, with the sector's innovative and international capabilities being recognized and valuations undergoing reassessment [1] - The National Medical Products Administration has recently released a priority approval list for high-end medical devices, which includes brain-computer interfaces, ultra-high field MRI, and surgical robots, all of which are expected to benefit [1] - In the short term, there are opportunities for performance and valuation recovery for certain stocks in Q4 and 2026, with some companies set to release annual performance forecasts in January, suggesting a focus on those with either above or below expected performance [1] Group 2 - The ChiNext Medical ETF (159377) tracks the Innovation Medicine Index (399275), which saw a daily fluctuation of 20%, focusing on innovative pharmaceutical sectors and selecting companies with high R&D investment and strong innovation capabilities [1] - The index aims to reflect the overall performance of leading companies in the pharmaceutical industry that combine growth potential with technological attributes, covering sectors such as biopharmaceuticals, chemical pharmaceuticals, traditional Chinese medicine, and medical services [1]